Conditions: Cancer-related Fatigue
Keywords: cancer fatigue
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 11
Healthy volunteers: no

Brief summary:
The primary objective of the study is to evaluate thyrotropin releasing hormone (TRH) as a treatment for cancer-related fatigue.

The central hypothesis of this pilot study is that TRH is more efficacious than placebo in alleviating cancer-related fatigue in patients with breast or prostate cancer.

Detailed description:

Arms:
arm 1: TRH arm 2: Placebo

Interventions: intervention 1: Thyrotropin releasing hormone (TRH) intervention 2: Placebo
Intervention descriptions: intervention 1: 0.5mg and 1.5mg intervention 2: Saline

Protocol document: